Chris Delany

Chris Delany has extensive work experience in the pharmaceutical and biotechnology industry. Chris is currently serving as the Senior Director of CMC Analytical Chemistry at Loxo Oncology at Lilly. Prior to that, they worked as the ADME Manager at Dicerna Pharmaceuticals, Inc. from 2019 to 2020 and as the Associate Director of Quality Control at Rezolute, Inc. from 2017 to 2019.

Chris also held the position of Associate Director of Pharmaceutical Development at Nivalis Therapeutics, Inc. from 2015 to 2017, where they were responsible for drug product development and analytical activities. In addition, they worked as a Sr. Research Scientist at N30 Pharmaceuticals from 2008 to 2015, providing analytical support for drug substance and drug product programs.

Their earlier experience includes roles such as Research Associate V in R&D at Cephalon from 1998 to 2008, Chemist II at Geneva Pharmaceuticals from 1993 to 1995, and Technician at Natural Resource Ecology Laboratory (NREL) from 1991 to 1992.

Overall, Chris Delany has a diverse background in analytical chemistry, pharmaceutical development, and quality control within the pharmaceutical industry.

Chris Delany received a Bachelor of Science degree in Biological Science with an emphasis in Cellular, Molecular, and Genetic from Colorado State University, where they studied from 1988 to 1992.